We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monitoring ANCA Levels Helps Predict Relapse of Systemic Vasculitis in Patients with Kidney Involvement

By LabMedica International staff writers
Posted on 28 Oct 2014
Repeated measurement of levels of anti-neutrophil cytoplasmic antibodies (ANCA) predicts likelihood of relapse in patients suffering from systemic vasculitis with kidney involvement.

Anti-neutrophil cytoplasmic antibodies are a group of autoantibodies, mainly of the IgG type, against antigens in the cytoplasm of neutrophil granulocytes (the most common type of white blood cell) and monocytes. More...
They are detected by a blood test in a number of autoimmune disorders, but are particularly associated with systemic vasculitis. The antibodies produced by patients with ANCA-associated vasculitis can damage blood vessels, and relapses of the disorder can cause severe and permanent damage to organs and other parts of the body.

Although the value of measuring ANCA during follow-up to predict a relapse has been controversial, investigators at Maastricht University (The Netherlands) postulated that measuring ANCA could be useful in patients with renal involvement but would be less valuable in patients with non-renal disease.

To test this theory, they monitored PR3-ANCA and MPO-ANCA levels in 166 consecutive patients with ANCA-associated vasculitis who were positive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA. Among the study group were 104 patients with kidney problems associated with the disease and 62 without.

During the follow-up period that averaged 49 months and included an average of 18 additional ANCA measurements, increase in ANCA levels was seen in 89 patients and 74 relapses were recorded. ANCA rises correlated with relapses in patients who presented with renal involvement but in comparison, associated only weakly with relapses in patients who presented with non-renal disease.

“By measuring ANCA levels in patients with kidney involvement, doctors can predict which patients are going to relapse. It is expected that by using ANCAs as a guideline, severe relapses necessitating dialysis can be prevented,” said senior author Dr. Jan Willem Cohen Tervaert, professor of medicine and immunology at Maastricht University.

The study was published in the October 16, 2014, online edition of the Journal of the American Society of Nephrology.

Related Links:

Maastricht University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.